Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.
about
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinibNilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration studyNilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Philadelphia-positive acute lymphoblastic leukemia: current treatment optionsPotential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.Management of chronic myeloid leukemia in blast crisis.Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.The Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia.Implementing the EffTox dose-finding design in the Matchpoint trial.BCR: a new target in resistance mediated by BCR/ABL-315I?Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.Second line small molecule therapy options for treating chronic myeloid leukemia.How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.Sequential Use of Second-Generation Tyrosine Kinase Inhibitor Treatment and Intensive Chemotherapy Induced Long-Term Complete Molecular Response in Imatinib-Resistant CML Patient Presenting as a Myeloid Blast Crisis.In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia.[Chronic myelogenous leukemia].[Tailored management of chronic myeloid leukemia].Chronische myeloische Leukämie
P2860
Q26751285-148A3E73-9D31-44DF-955F-AE4E670B7339Q33423072-B3E6F652-8FF7-476E-A0BA-BF080AD58E31Q34639998-D4C68630-204C-482B-A108-7F72C5C15565Q37026032-A135C5A9-67E6-4042-8585-5C1175F08D5DQ38016343-B2FF1E1C-DC1C-47DB-8F48-499E6295AFB6Q38139571-D46EEE32-A6B0-406D-AD09-05F4510DE410Q38392673-F29F6033-168E-4382-A5BB-E35DA9AB207CQ38392682-CF6D332C-11E0-4E97-AF45-CB2A096B901DQ38436037-AE08A0C5-1637-4A5A-970C-B5ACA2067DAFQ38478174-5508C69A-BA93-402E-8ACA-CA872A829997Q38642952-D42DCDA6-964C-4DE7-8D3A-CECA72AFC917Q38654251-1AA9D7B1-32E8-4E6C-AA50-B538F5A6FE01Q38710583-86045F8B-248E-43D4-9D99-AF32499E2A62Q38767908-FDBCAEF4-4495-4D6A-BC0F-6FBE37AEED01Q38789049-3B9682E2-EE75-42BE-BE9E-81DD5F373E46Q38845834-A4287B40-41E8-4D43-A26C-A6C259F5DBBDQ38940615-A26A5AEE-34FE-4824-86CC-6FC781BFE48EQ41402735-76F03FB2-5DB8-42D3-A3F0-47B8CB6E6BFAQ48119645-0EA9272A-094C-40AD-8C7A-E56210319C8EQ51066255-F696B1C1-460E-4047-84A0-4F020AD88F76Q54167458-942BC789-FEA7-4BF3-954A-954F6A8EA37AQ54398375-7E298B7C-D1C2-455F-A105-EB7AF1E98B16Q58023770-475F7EB2-2AAC-46F7-9D7B-6D246D3FF9C9
P2860
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Nilotinib is effective in imat ...... oid leukemia in blastic phase.
@ast
Nilotinib is effective in imat ...... oid leukemia in blastic phase.
@en
type
label
Nilotinib is effective in imat ...... oid leukemia in blastic phase.
@ast
Nilotinib is effective in imat ...... oid leukemia in blastic phase.
@en
prefLabel
Nilotinib is effective in imat ...... oid leukemia in blastic phase.
@ast
Nilotinib is effective in imat ...... oid leukemia in blastic phase.
@en
P2093
P50
P356
P1433
P1476
Nilotinib is effective in imat ...... loid leukemia in blastic phase
@en
P2093
H M Kantarjian
M Baccarani
N J Gallagher
P D le Coutre
R E Blakesley
S L Goldberg
P2888
P304
P356
10.1038/LEU.2011.355
P577
2011-12-13T00:00:00Z
P5875
P6179
1045865761